GSK3 has a profound involvement in mood disorders. Firstly, mood stabilizers and antidepressants inhibit GSK3 [5, 6] . Both fast-acting (ketamine) [7] and conventional antidepressants [4] , as well as antipsychotics [4] , have been shown to promote the inhibitory serine phosphorylation of GSK3. Lithium exerts dual actions to inhibit GSK3, both by competing with Mg 2+ binding in the active site of the enzyme, and also by promoting the inhibitory serine phosphorylation of GSK3 [8] . Furthermore, depression-like behavior in rodents are reduced by pharmacological [9, 10] or genetic [11] [12] [13] [14] reduction of GSK3 activity. Lithium has been shown to reduce depressive behavior in mice as efficiently as knocking down one allele of GSK3β [13] , and to promote the effects of the antidepressant serotonin reuptake inhibitors [15, 16] .
Other small-molecule GSK3 inhibitors also attenuated depressive behavior in rodents [10, 11, 13] . Serotonergic signaling deficiency, which may occur in depression, activates GSK3 [6] . Also, GSK3 is inhibited by neurotrophins, such as brain-derived neurotrophin factor [17] , which may be deficient in depression [18] . Conversely, because the inhibitory serines in GSK3α/β were mutated to alanines, GSK3 knockin mice that express constitutively active GSK3 at the physiological level exhibit increased susceptibility to depressive-and maniclike behavior [19] . Furthermore, depression induced in mice by the learned helplessness paradigm reduced inhibitory serine-phosphorylated GSK3 in the hippocampus and cerebral cortex. Similarly, activated GSK3 was found in the nucleus accumbens in mice after social defeat stress [20] , demonstrating that active GSK3 is associated with depressive behavior. Active GSK3 also promotes manic-like behavior, measured by assessing locomotor activity [4] . Drugs inducing locomotor activity, such as amphetamine, also decrease the serine-phosphorylation of GSK3. [21] . Finally, studies of human serum [22] , human postmortem brain [23] and GSK3 polymorphisms [24] further implicate dysregulated GSK3 in promoting mood disorders.
Altogether, it is now well accepted that GSK3 is active in mouse models of both depression and mania, although this seems to be regulated by different pathways in the two conditions. The activation of GSK3 associated with depression may be dependent on neuronal circuitry related to deficiencies in the serotonergic or neurotrophin pathways, whereas the activation of GSK3 associated with manic-like behavior seems to be mediated by the action of GSK3 in the dopaminergic pathway [4] . A variety of actions of GSK3 have been associated with its regulation of mood, including regulation of apoptosis, neurogenesis and inflammation. This review focuses on the inflammatory effects of GSK3 that may be related to mood disorders.
GSK3 Promotes Inflammation

GSK3
Regulates the Innate Immune System GSK3 was first discovered to promote the production of proinflammatory cytokines and to inhibit anti-inflammatory cytokine production in monocytes in response to Toll-like receptor, TLR, activation [25] . These findings showed that GSK3 shifts the balance towards proinflammatory responses, and that inhibiting GSK3 favors antiinflammatory responses in response to TLR activation [26] . These actions on cytokine production have been confirmed in several different cell types, including macrophages, dendritic cells and brain immune cells, including microglia and astrocytes. Therefore, besides inhibiting peripheral immune responses, GSK3 inhibitors also reduce neuroinflammation [26] . GSK3 is thought to promote phosphorylation of NF-κB and STAT3, which are key regulators of the production of proinflammatory cytokines, while inhibiting CREB and AP-1, which are responsible for increased expression of the anti-inflammatory cytokine IL-10 [26] . The mTOR pathway has also been shown to reduce inflammatory cytokine production by inhibiting GSK3 [27] . As a consequence of the inhibition of inflammatory cytokine production by GSK3 inhibitors, treatment with GSK3 inhibitors protect 70% of mice from an otherwise lethal septic shock, and also provide protection from a variety of other inflammatory diseases [26] . and TGF-β production [28] .
Because GSK3 is a critical inducer of proinflammatory cytokines, and because cytokines are required for CD4+ T cells to differentiate, GSK3 has also been shown to regulate the differentiation of subsets of Th cells. GSK3 promotes the production of Th1 and Th17 cells, and does not affect Th2 cell differentiation, but its role in the regulation of Tregs is not established, as some researchers found that GSK3 inhibition promotes Treg production [29] , while others did not find an effect [30, 31] . In addition to regulating the production of cytokines that influence Th cell differentiation, GSK3 also intrinsically controls the differentiation of Th1 and Th17 cells by regulating some of the key transcription factors responsible for the differentiation of Th1 and Th17 cells [30] [31] [32] . Thus, GSK3 promotes STAT1 activation in Th1 cells, but does not affect STAT4 activation, and GSK3 inhibitors reduced Tbet expression during Th1 differentiation. GSK3 promotes STAT3 activation in Th17 cells without affecting the master regulator transcription factor of Th17 cells, RORγT. This suggests that GSK3 acts early in the differentiation of Th1 and Th17 cells. GSK3 expression is also increased in CD4+ T cells during differentiation of Th1 and Th17 cells, although the mechanism whereby GSK3 expression increases remains unknown. Although the actions of GSK3 in Th1 and Th17 cell differentiation are mediated by cytokines and STATs, it is unlikely that this is the only mechanism whereby GSK3 controls Th17 differentiation. There seems to be a selectivity regarding the isoform of GSK3 involved in the regulation of Th17 cells. Thus, GSK3β seems to promote Th17 cells induced by IL-6 and TGF-β [30, 31] , whereas GSK3α suppressed Th17 differentiation induced by IL-1, an action attributed to the inhibition by GSK3α of Akt and mTOR activation by IL-1 [32] . It has also been proposed that regulation of β-catenin by GSK3 in response to TGF-β was an important action of GSK3 in the regulation of Tregs [29] . GSK3 also affects the survival of T cells. For example, activated T cell death requires GSK3 activity, and inhibition of GSK3 promotes the survival of T cells [33] .
Altogether, although most of the actions of GSK3 that have been described concern the regulation of cytokine production by the innate immune system, it appears that GSK3 is also implicated in the regulation of CD4+ T cell differentiation independently of its action on cytokine production by the innate immune system. Indeed, mice lacking GSK3β only in T cells are resistant to induction of experimental autoimmune encephalomyelitis (EAE), the mouse model of multiple sclerosis, whereas mice lacking GSK3α in T cells develop EAE similar to their littermate controls [30] . Because EAE is highly dependent on the pathogenicity of Th1 and Th17 cells, this finding showed that the intrinsic regulation by GSK3 of Th cell differentiation is a critical action of GSK3 in T cells.
Mood Disorders and Inflammation
With a lifetime incidence of ∼ 20% in the USA, mood disorders (depression and bipolar disorder) are prevalent diseases [34, 35] . Currently there are significant inadequacies in available treatments. Many patients fail to improve after antidepressant treatment or terminate their treatment prematurely. Alterations of the immune system, especially increased markers of inflammation, have been found to be associated with mood disorders in many studies ( fig. 1 ) . Thus, susceptibility to depression appears to be increased by inflammation, and therapeutic responses to antidepressants are impaired by inflammation. In the serum of some patients with major depression or bipolar disorder, there is an elevation of the proinflammatory cytokines IL-6, IL-1β and TNF-α. Moreover, administration of lipopolysaccharide [36] or IFN-α [37] promotes depressive symptoms in humans. Administration of anti-inflammatory drugs, such as cyclo-oxygenase inhibitors or etanercept, improve mood in patients with inflammatory diseases. In rodents, it has been shown that these behaviors could be recapitulated using either lipopolysaccharide, LPS, to induce 'sickness behavior' or the administration of cytokines [38] . Furthermore, psychological stress is sufficient to increase proinflammatory cytokine production and to induce depressive behavior [39] . Therefore, there is accumulating evidence that inflammatory cytokines are closely associated with depression in patients and with depressive-like behavior in rodents. Miller's group [42] recently reported the results of a clinical trial in which administration of an anti-TNF antibody in depressed patients ameliorated depression in a subset of patients that had elevated inflammatory markers, suggesting that all depressed patients were not equivalent in terms of disease and that a classification of depressed patients according to their inflammatory status may be useful. However, neither the source (central or peripheral) nor the exact cytokine to target to prevent depressive behavior has been identified yet. Nevertheless, it is thought that the innate immune system plays a critical role in the induction of depressive behavior. It has been proposed that GSK3 could promote depressive behavior by promoting the production of proinflammatory cytokines, but currently there is no report of the direct involvement of GSK3 in cytokine-induced depressive behavior. It has been reported that in response to LPS, GSK3 knockin mice exhibit increased sickness behavior in the tail suspension test, and this was associated with increased IL-6 production [19] , but further investigations are required to determine if promotion of inflammation by GSK3 contributes to the detrimental role of GSK3 in mood disorders.
The impact of the adaptive immune system, especially T cells, is not well understood in the etiology of mood disorders. Altered stress-induced proliferation and function of T cells isolated from depressed patients have been reported, which could result from increased Fas-mediated apoptosis, reduced T cell response to glucocorticoids, or increased cytokine levels responsible for modulating T cell subtype production and responses [40] . Because cytokines, especially IL-6, are elevated in a significant number of depressed patients, and since it is difficult to identify an individual cytokine responsible for promoting depressive behavior, pinpointing downstream events of cytokines may aid the understanding of the role of inflammation in depression. Because Th17 cells are highly dependent on the production of IL-6, and IL-6 is elevated in depressed patients, Th17 cells were examined and shown to promote depressive behavior in mice [41] . GSK3 promotes the production of Th17 cells, as lithium blocked Th17 cells induced during depressive behavior, whereas, in contrast, GSK3 knockin mice have elevated Th17 cells, which correlates with GSK3 knockin mice being more susceptible to depression. These findings suggest that one way in which GSK3 may promote depressive behavior is by promoting the production of Th17 cells, as well as promoting inflammation.
Altogether, there is accumulating evidence converging on the role of GSK3 in promoting inflammation and suggesting that this may impact depressive behavior ( fig. 1 ). However, further investigations are required to decipher the role of GSK3 in depression. Nevertheless, inflammation appears to be a potential new therapeutic strategy to reduce depressive behavior. The challenge remaining is to determine whether this will be sufficient to be therapeutic for depressive behavior, and for this the source of the insult causing alterations in cytokines and T cells needs to be identified.
